Enters German Market Euro3.2m Manufacturing & Supply Agmt
| Stock | Bioxyne Ltd (BXN.ASX) |
|---|---|
| Release Time | 18 Jun 2025, 9:12 a.m. |
| Price Sensitive | Yes |
Bioxyne Enters German Market with €3.2m Manufacturing & Supply Agreement
- Bioxyne's subsidiary Breathe Life Sciences (BLS) executes agreement to supply minimum 1,600 kg of GMP medical cannabis flower API and finished product to Germany
- BLS registered 14 Australian cannabis strains with BfArM, authorizing import and distribution in Germany
- BLS expects to generate minimum A$5.6m (€3.2m) revenue in FY2026 from the agreement
Bioxyne Limited (ASX: BXN), through its subsidiary Breathe Life Sciences (BLS), has announced that it has entered the German cannabis market by executing a commercial agreement to supply a minimum of 1,600 kg of GMP medical cannabis flower API and finished product. The cannabis flower will be manufactured by BLS under EU GMP certified standards for export to Germany. The supply agreement commits Farmakem d.o.o. as the Buyer and Adrex Pharmaceuticals GmbH, a leading importer, manufacturer, and distributor of Cannabis in Germany, to purchase and distribute the minimum 1.6 tons (1,600kg) of Cannabis Flower Product manufactured by BLS in FY2026. BLS and Adrex have also registered 14 of BLS's Australian manufactured cannabis strains with BfArM (the largest drug approval authority in Europe) in Germany, which authorizes the import and distribution of the product in the German market. The two companies are also working together to establish BLS brands, including Dr Watson®, in the German market.Under the agreement, BLS expects to generate a minimum of A$5.6m (€3.2m) in revenue in FY2026. The first delivery of 580kg is scheduled for September 2025, with a second shipment planned for November.
BLS expects to generate a minimum of A$5.6m (€3.2m) in revenue in FY2026 from the manufacturing and supply agreement.
Bioxyne is positioned for significant growth in FY2026, attributable to further expansion of its business in Australia as well as entry into new high-growth opportunity markets including the UK, Germany and other EU countries. The German medical cannabis market is growing rapidly following deregulation in early 2025 and is expected to overtake Australia's $1b-per-year medcan market in 2026.